Company: HURA
Filing Date: 2025-09-18
Form Type: S-1/A
Source: 0001193125-25-207395
Chunk: 181

Company: TuHURA Biosciences, Inc./NV
Filing Date: 2025-09-18
Form: S-1/A
Chunk 181
---
, a quantitative impairment test is performed.

Recently Issued and Adopted Accounting Pronouncements

A description of recently issued and adopted accounting pronouncements that may potentially impact our financial position and results of operations is disclosed in Note 2 to our financial statements.

Off-Balance Sheet Arrangements

During the periods presented, we did not have, nor do we currently have, any off-balance sheet arrangements as defined under SEC rules.

Quantitative and Qualitative Disclosures about Market Risk

We are exposed to market risks in the ordinary course of our business. These risks primarily include interest rate risks and inflation risks. Periodically, we maintain deposits in accredited financial institutions in excess of federally insured limits. We deposit our cash in financial institutions that we believe has high credit quality and have not experienced any losses on such accounts and does not believe we are exposed to any unusual credit risk beyond the normal credit risk associated with commercial banking relationships.

Interest Rate Risk

Our cash consists of cash in readily-available checking accounts. We may also invest in short-term money market fund investments. Such interest-earning instruments carry a degree of interest rate risk; however, historical fluctuations in interest income have not been significant.

Inflation Risk

Inflation generally affects us by increasing our cost of labor and research and development contract costs. We do not believe inflation has had a material effect on our results of operations during the periods presented.**

<div align='center'>116</div>

MANAGEMENT Management and the Board of Directors The following table sets forth the persons who serve as TuHURA’s executive officers and directors, and their ages as of September 11, 2025:

| Name                                  |     | Age |     | Position(s)                          |
| Executive Officers                    |     |     |     |                                      |
| James Bianco, M.D.                    |     |  69 |     | Chief Executive Officer and Director |
| Dan Dearborn                          |     |  58 |     | Chief Financial Officer              |
| Non-Employee Directors                |     |     |     |                                      |
| James Manuso, Ph.D., MBA              |     |  76 |     | Director and Chairman of the Board   |
| Alan List, M.D.                       |     |  70 |     | Director                             |
| George Ng                             |     |  51 |     | Director                             |
| Robert E. Hoffman Craig Tendler, M.D. |     |  59 
  66 |     | Director Director                    |

Executive Officers James Bian